This Article Full Text Full Text (PDF) All Versions of this Article: 93/9/3295    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Google Scholar Articles by Horwitz, K. B. Articles by Sartorius, C. A. PubMed PubMed Citation Articles by Horwitz, K. B. Articles by Sartorius, C. A. Pubmed/NCBI databases Medline Plus Health Information Breast Cancer Related Collections Endocrine Oncology Female Endocrinology

Progestins in Hormone Replacement Therapies Reactivate Cancer Stem Cells in Women with Preexisting Breast Cancers: A Hypothesis

Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado 80045

Address all correspondence and requests for reprints to: Kathryn B. Horwitz, Ph.D., Distinguished Professor, Anschutz Medical Campus at Fitzsimons, Department of Medicine, Endocrinology MS 8106, PO Box 6511, Aurora, CO 80045-7113. E-mail: kate.horwitz{at}uchsc.edu.

Why does hormone replacement therapy (HRT) with estrogens plus progestins increase the risk of breast cancer? First, experimental estrogen receptor-positive (ER⁺) and progesterone receptor-positive (PR⁺) human breast cancers contain a rare subpopulation of ER^–, PR^– cancer stem cells. Especially in small, nascent ER⁺, PR⁺ tumor colonies, progestins, but not estrogens, reactivate cells with ER^–, PR^– stem-like properties. Second, there is a reservoir of occult, undetected, preinvasive breast cancer in some women who are candidates for HRT. We propose that women who develop breast cancer while on estrogens plus progestins harbor undiagnosed nascent disease before the start of therapy. The progestin component, in a nonproliferative step, reactivates receptor-negative cancer stem cells within such germinal, perhaps even dormant tumors. After reacquiring receptors, these tumor cells are expanded by the mitogenic properties of estrogens. We argue that screening methods need to be improved to detect small, preexisting malignancies prior to the start of HRT. Women harboring such disease should be excluded from regimens that include systemic progestins.

This article has been cited by other articles:

				K. B. Horwitz Commentary: The Year in Basic Science: Update of Estrogen Plus Progestin Therapy for Menopausal Hormone Replacement Implicating Stem Cells in the Increased Breast Cancer Risk Mol. Endocrinol., December 1, 2008; 22(12): 2743 - 2750. [Abstract] [Full Text] [PDF]